Hoolivus, Uuendusmeelsus, Pädevus ja Usaldusväärsus
CD20 B-rakkudel
Immuunanalüüsi osakond
CD20 on CD19 kõrval teine peamine B-rakkude diferentseerumise marker. CD20 lisandub B-rakkude pinnale alates pre-B staadiumist, mistõttu enamik küpseid B-rakke on CD19+/CD20+. CD20 puudub mitteküpsetel eellastel ja ka plasmarakkudel.
CD20 on mitmete autoimmuunhaiguste ja B-rakuliste hematoloogiliste haiguste korral immuunravi märklauaks. CD20-vastaste monoklonaalsete antikehade (Rituximab, Obinutuzumab jt) toimel B-rakud hävivad. Ravimi toime püsib mitmeid kuid – perifeersete B-lümfotsüütide arv taastub esialgsele tasemele umbes 3.–12. kuul pärast ravimi manustamist.
CD20 ja CD19 puudulikkust või märgatavat vähenemist on täheldatud primaarse humoraalse immuunpuudulikkuse korral, nagu nt X-seoseline agammaglobulineemia ja autosoomne retsessiivne agammaglobulineemia.
Uuritav materjal, selle võtmine, saatmine ja säilitamine
Katsuti
K2E/K3E-katsuti (lilla kork)
Minimaalne kogus
1 mL venoosset verd
Säilivus
Toatemperatuuril kuni 24 tundi. Mitte külmutada! Hoida päikesekiirguse eest!
Analüüsi tegemise aeg: tööpäeviti, vastus 3 tööpäeva jooksul
Anti-CD20 ravi patsientidel CD19+/CD20+ rakud puuduvad või nende arv on oluliselt vähenenud võrreldes ravieelse näitajaga
Kasutatud kirjandus
Marshall M, et al., Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? Front Immunol, 04 October 2017.
Delgado S., et al., Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. Journal of Neurology (2024), 271(4):1515–1535.
Payandeh Z. et al., The applications of anti-CD20 antibodies to treat various B cells disorders. Biomedicine & Pharmacotherapy, (2019) Jan:109:2415-2426.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
